Format

Send to

Choose Destination
See comment in PubMed Commons below
Exp Cell Res. 2013 Apr 1;319(6):777-8. doi: 10.1016/j.yexcr.2013.01.006. Epub 2013 Jan 16.

Luteolin and its inhibitory effect on tumor growth in systemic malignancies.

Author information

1
74 crossing place, Mechanicsville, VA, USA. shailendrakapoor@yahoo.com

Abstract

Lamy et al have provided interesting data in their recent article in your esteemed journal. Luteolin augments apoptosis in a number of systemic malignancies. Luteolin reduces tumor growth in breast carcinomas. Luteolin mediates this effect by up-regulating the expression of Bax and down-regulating the expression of Bcl-xL. EGFR-induced MAPK activation is also attenuated. As a result there is increased G2/ M phase arrest. These effects have been seen both in vivo as well as in vitro. It also reduces ERĪ± expression and causes inhibition of IGF-1 mediated PI3K-Akt pathway. Luteolin also activates p38 resulting in nuclear translocation of the apoptosis-inducing factor. Simultaneously it also activates ERK. As a result there is increased intra-tumoral apoptosis which is caspase dependent as well as caspase independent.

PMID:
23333558
DOI:
10.1016/j.yexcr.2013.01.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center